3 results
PEMbrolizumab Plus Lenvatinib In Second Line And Third Line Malignant Pleural MEsotheLiomA Patients.
Primary: 1. To determine the objective response rate (ORR), defined by Modified (i)RECIST criteria for pleural mesothelioma, of the combination of pembrolizumab - lenvatinib in pre-treated patients with MPM. Secondary:1. To describe the safety of…
Approved WMORecruiting
• To assess the tolerability and safety of the investigational medicinal product
Approved WMORecruiting
Objectives:To compare the efficacy of Atropine 0.05% to Atropine 0.5% treatment in European children with progressive myopia, and to evaluate the safety, adherence, and reasons for nonresponse.To create an online BIG DATA registry for myopia…